MétaCan
Menu
← Back to cohort
Record W4310108940 · doi:10.1182/blood-2022-163661

Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

2022· article· en· W4310108940 on OpenAlexaffabout
Rayan Kaedbey, Kevin A. Hay, Esther Masih‐Khan, Moustafa Kardjadj, Arleigh McCurdy, Michael P. Chu, Víctor H. Jiménez‐Zepeda, Richard LeBlanc, Kevin Song, Hira Mian, Martha Louzada, Michaël Sébag, Tony Reiman, Darrell White, Christopher P. Venner, Julie Stakiw, Rami Kotb, Muhammad Aslam, Debra Bergstrom, Engin Gul, Donna Reece

Bibliographic record

VenueBlood · 2022
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsMemorial University of NewfoundlandRegina Qu'Appelle Health RegionSpinal Cord Injury BCQueen Elizabeth II Health Sciences CentreDalhousie UniversitySaint John Regional HospitalLondon Health Sciences CentreMcMaster UniversityUniversity of CalgaryPrincess Margaret Cancer CentreVancouver General HospitalUniversity of British ColumbiaHôpital Maisonneuve-RosemontUniversity Health NetworkCancerCare ManitobaOttawa HospitalMcGill University Health CentreMcGill UniversityWestern UniversityUniversity of TorontoTerry Fox Research InstituteJewish General Hospital
Fundersnot available
KeywordsMedicineSalvage therapyMultiple myelomaTransplantationOncologyMaintenance therapySurgeryAutologous stem-cell transplantationStem cellInternal medicineChemotherapy

Abstract

fetched live from OpenAlex

Background: Salvage autologous stem cell transplantations (ASCT) in the setting of relapsed multiple myeloma have historically been an important therapeutic option. There have not been any comparative studies looking at this approach in the era of novel therapeutic agents such as monoclonal antibodies and emerging immunotherapies. It is important to have a real world benchmark when understanding the landscape of potential treatments in this space. Maintenance therapy post frontline autologous stem cell transplantation has become standard of care due to the important improvement in progression free survival (PFS) as well as overall survival (OS). However, little is known about the impact of maintenance post-salvage transplant. The objectives of this study are to define PFS and OS for salvage transplants with or without maintenance and describe the outcomes by types of maintenance utilized in this setting. Secondly, to redefine the optimal duration of remission post-first transplant in the maintenance era that would justify a second autologous transplant. Historically, in the pre-maintenance era, 24 months was demonstrated as an optimal remission post first transplant to gain benefit from a second salvage transplant. Methods: This is a Canadian multicentre retrospective study utilizing the Canadian Myeloma Research Group Database, a national database with input from 16 Canadian centres hosting over 8700 patients. All patients included in the study had undergone a salvage ASCT between Jan 2012 to Dec 2021 at any line of treatment. Results: Three hundred and fifty-two patients met eligibility for inclusion in this analysis. Baseline characteristics are portrayed in table 1. The median PFS (mPFS) for patients undergoing salvage transplant with (n= 179) and without (n=173) maintenance were 42.1 (34.8-53.6) and 24.2 (20.7-28.1) months respectively. The mOS was 101m (97.6-NYR) in the maintenance group and NYR (53.7-NYR) in the no maintenance group. In patients who received any type of maintenance post ASCT1 (n=169) and had a duration of response greater than 36m to the first transplant, the salvage transplant without maintenance (n=54) provided a mPFS of 17.3m (15.2-35). In a similar group that had greater than 36m response and received maintenance after ASCT1 (n=92), the addition of maintenance after the salvage transplants significantly improved the mPFS to 34.8m (26.5-51, p=<0.01). Patients that received maintenance post ASCT1 and had less than 36m PFS represent a higher risk group. In these patients, a salvage transplant without post salvage maintenance (n=10), yielded a mPFS of 9.9m (8.5-NYR). The addition of post salvage maintenance, however, significantly improved outcomes for this group as well (n=13) to a mPFS of 29.1(14.6-NYR). The most common type of maintenance post-salvage was imid based (55.9%), followed by PI based (30.2%) and then PI+imid (7.8%). Overall response rates for salvage transplants with or without maintenance therapy were 94.1% and 89.9% respectively and > VGPR were 75.3% and 67.6% respectively. The mPFS based on type of maintenance therapy are portrayed in figure 1. There was no statistically significant difference in OS based on types of maintenance therapy. Further analyses are pending and will be presented. Conclusion: Salvage transplants followed by maintenance therapy in the first relapse space provide a meaningful duration of remission and this remains a good treatment option particularly in those with a long remission after their first ASCT. As novel immunotherapies such as CAR-T and bispecific antibodies move into earlier lines of treatment, this data could serve as an important real world benchmark when evaluating the landscape for these therapies. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.040
Threshold uncertainty score0.080

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0010.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.277
Teacher spread0.261 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2022
Admission routes2
Has abstractyes

Explore more

Same venueBlood→Same topicMultiple Myeloma Research and Treatments→French-language works237,207→